The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors

BACKGROUND: Sodium glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of hard cardiovascular endpoints in type 2 diabetes mellitus (T2DM) patients with/without established cardiovascular diseases. Whether SGLT2i is associated with a lower risk of new-onset atrial fibrillation (AF) in T2DM p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ling, Ann Wan-Chin, Chan, Cze-Ci, Chen, Shao-Wei, Kao, Yi-Wei, Huang, Chien-Ying, Chan, Yi-Hsin, Chu, Pao-Hsien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648323/
https://www.ncbi.nlm.nih.gov/pubmed/33158436
http://dx.doi.org/10.1186/s12933-020-01162-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648323/
https://www.ncbi.nlm.nih.gov/pubmed/33158436
http://dx.doi.org/10.1186/s12933-020-01162-w

Ejemplares similares